CoreWeave: The Most Hated AI Stock - Now A Screaming Buy (Rating Upgrade)

CoreWeave, Inc. is a strong AI infrastructure buy after record Q3 growth, reduced risk, and major contracts. Click here to ...

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply ...

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S.

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec.

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...